INTS3 and diffuse large B-cell lymphoma: A global low mutation rate (from 0 to 9.09%) was found, with INTS3 and INTS7 being frequently mutated in lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) (8.16%) and in pancreas adenocarcinoma (PAAD) (9.1%), respectively.